Related Experiment Video

Updated: Jun 4, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Estrogen receptors, antiestrogens, and non-small cell lung cancer

T A Bogush1, E A Dudko, A A Beme

  • 1Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow 115478, Russia. bogush@orc.ru

Biochemistry. Biokhimiia
|February 15, 2011
PubMed

Insights

Estrogen receptors (ERα and ERβ) are key in non-small cell lung cancer (NSCLC) development. ERβ is crucial for estrogen-stimulated proliferation and a favorable prognostic marker in NSCLC.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Estrogen receptors (ERα and ERβ) are implicated in various cancers, including breast cancer.
  • Their role in non-small cell lung cancer (NSCLC) genesis and progression is increasingly recognized.

Purpose of the Study:

  • To review the expression and function of ERα and ERβ in NSCLC.
  • To explore the prognostic significance of ERβ in NSCLC.
  • To examine the interplay between estrogen receptor and EGFR signaling pathways in NSCLC.

Main Methods:

  • Review of existing literature on ER expression in NSCLC cell lines, human, and animal tumors.
  • Analysis of data on estrogen-stimulated proliferation and antiestrogen effects.
  • Examination of interactions between ER and EGFR signaling pathways.

Main Results:

  • ERβ is expressed in over half of NSCLC cases, unlike ERα.
  • ERβ plays a critical role in estrogen-induced cell proliferation in NSCLC.
  • ERβ expression serves as a favorable prognostic marker for NSCLC patients.

Conclusions:

  • Estrogen receptors, particularly ERβ, are significant in NSCLC development and progression.
  • ERβ expression is associated with a better prognosis in NSCLC.
  • Targeting estrogen receptors and EGFR pathways may offer novel therapeutic strategies for NSCLC.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...